



STATE MEDICAID DUR BOARD MEETING
 THURSDAY, March 14, 2013
 7:00 a.m. to 8:30 a.m.
 Cannon Health Building
 Room 125



MINUTES

Board Members Present:

Neal Catalano, PharmD.
 Joseph Miner, M.D.
 Jay Aldous, DDS

Mark Balk, PharmD.
 Tony Dalpiaz, PharmD.
 George Hamblin, R.Ph.

Board Members Excused:

Brad Hare, M.D.
 Mr. Kumar Shah

Cris Cowley, M.D.
 Kathy Goodfellow, R.Ph.

Dept. of Health/Div. of Health Care Financing Staff Present:

Tim Morley, R.Ph.
 Lisa V Hunt, R.Ph.
 Trevor Smith, B.S., C.Ph.T
 Merelynn Berrett, R.N.

Robyn Seely, PharmD.
 Bobbi Hansen, C.Ph.T.
 Richard Sorenson, R.N.

Other Individuals Present:

Joanita Lake, UofU
 Anne Marie Licos, MedImmune
 Kim Eggert, Gilead
 Erik Carriano, Boeringer Ingelheim
 Brian Larson, UofU
 Rick Realsen, Merck
 Mark Hagger, Boeringer Ingelheim

Charissa Anne, J&J
 Wayne Roberts, GSK
 Scott Larson, BMS
 Nicole Kesty, AstraZeneca
 Efrain Alton, Merck
 Lori Howarth, Bayer
 Linda Craig, AstraZeneca

Meeting conducted by: Neal Catalano, PharmD

1. **Welcome** - Neal Catalano opened the meeting.
2. **Housekeeping** – Robyn Seely reminded guests and board members to sign in. She also announced that Neal Catalano’s board chairmanship will be up soon.
3. **P&T Committee report** – Lisa Hunt addressed the board. She reported that the P&T committee will be reviewing multiple sclerosis agents (recently added to the marketplace, since the class was last reviewed). She also provided the tentative P&T schedule to each of the board members. Lisa Hunt reported to the board some information regarding supplemental rebates on DPP-4 inhibitors and the effects of possible prior authorization (step-through therapy) criteria.

4. **Approval of prior meeting minutes** – The January minutes were re-approved due to some amendments made. Mark Balk made a motion to approve the amended January minutes. Joe Miner seconded the motion. The motion was approved unanimously. George Hamblin made a motion to approve the February meeting minutes. Tony Dalpiaz seconded the motion. The motion was approved unanimously by the board.
5. **DPP4 Inhibitors** – Joanita Lake summarized the prior months DPP-4 inhibitor presentation and restated the recommendations of the University of Utah Drug Information Center. The recommendations are that all DPP-4 inhibitor prescriptions require a prior authorization.

Due the information provided by Lisa Hunt regarding supplemental rebates Robyn Seely presented the following recommended prior authorization criteria to the board:

- A diagnosis of Type 2 Diabetes Mellitus.
 - 18 years of age or older.
 - Documentation indicating failure of one or more antidiabetic medications (metformin, sulfonylurea, or insulin) at maximum tolerated doses.
- Initial authorization granted for 6 months. Reauthorizations granted with an updated letter of medical necessity and documented improvement in HbA1c since the beginning of the initial PA period.

Robyn Seely stated that the presented criteria can be programmed to automatically search client medication and diagnosis profiles to see if requirements are met. If the system does not automatically find the requirements a written request will have to be submitted by the prescriber.

Public comment: Rick Realson, Health Science Associate, Merck. Rick spoke to the board requesting that the DPP-4 inhibitor class remaining open and available with no prior authorization requirement.

Board action: Joe Miner made a motion to accept the presented criteria (listed above in meeting minutes). Mark Balk seconded the motion. The motion was approved unanimously.

Joe Miner made an amendment to the initial motion in to change the presented criteria authorization and reauthorization periods to 1 year each. Mark Balk seconded the motion. The motion was approved unanimously.

6. **Open Meeting Act training** – Milda Shibonis, J.D. provided open meeting act training to the board. This training is required annually.
7. The next DUR Board meeting is scheduled for Thursday, April 11, 2013.

Minutes prepared by Bobbi Hansen.
There were no petitions to review in March.